Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.059 CHF | +0.34% | +7.27% | +43.90% |
Apr. 17 | Santhera Pharmaceuticals Terminates Cystic Fibrosis Drug License Deal with Spexis | MT |
Apr. 17 | Swiss Court OKs Moratorium Extension for Spexis | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationAnnual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+43.90% | 4.36M | |
-4.66% | 86.13B | |
+1.32% | 39.82B | |
-19.27% | 30.42B | |
+57.86% | 25.23B | |
-17.69% | 11.6B | |
-43.00% | 11.51B | |
-9.14% | 11.95B | |
+5.24% | 8.71B | |
-8.42% | 8.12B |
- Stock Market
- Equities
- POLN Stock
- News Spexis AG
- Basilea Pharmaceutica to Buy Preclinical Antibiotics Program Targeting Gram-negative Bacteria from Spexis